Skip to main content
Equibles
BMRN logo

BMRN · Biomarin Pharmaceutical Inc · Metrics

Track BMRN — free

Use BMRN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMRN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.23 +0.53 (+0.93%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$11.09B
Shares
193.69M
Volume · Nov 13 1.47M Avg daily vol (3M) 2.19M

BMRN metrics

109 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$57.23
Market cap
$11.09B

Price action

23 metrics
Price change (1W)
+2.1%
Price change (30D)
+2.1%
Price change (3M)
-15.0%
Price change (6M)
+10.5%
Price change (YTD)
-3.7%
Price change (1Y)
+5.6%
Trailing year
Price change (5Y)
-30.0%
52-week high
$70.24
52-week low
$49.67
Change from 52-week high
-18.5%
Change from 52-week low
+15.2%
Annualized volatility
35.4%
Annualized volatility (3M)
27.4%
Implied volatility (30D)
35.2%
IV rank (1Y)
26.5
IV percentile (1Y)
17.9
Beta
0.4
RSI (14D)
50.1
Price vs SMA 50
-2.8%
Price vs SMA 200
-2.1%
Avg volume (3M)
2.19M
Relative volume
0.7
Average dollar volume
$131.01M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
193.69M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.0×
reciprocal yield 25.2%
EV / EBITDA
38.3×
reciprocal yield 2.6%
EV / EBIT
127.5×
reciprocal yield 0.8%
P / sales
3.0×
reciprocal yield 33.0%
P / book
1.8
reciprocal yield 56.4%
FCF yield
5.0%
TTM · current market cap
Buyback yield
—
P / FCF
19.9
reciprocal yield 5.0%
P / operating cash flow
16.4
reciprocal yield 6.1%
Earnings yield
-0.2%

Historical valuation

8 metrics
P / E historical average (3Y)
58.8×
reciprocal yield 1.7%
P / E historical average (5Y)
165.6×
reciprocal yield 0.6%
EV / revenue historical average (3Y)
3.8×
reciprocal yield 26.2%
EV / revenue historical average (5Y)
3.8×
reciprocal yield 26.2%
EV / EBIT historical average (3Y)
61.9×
reciprocal yield 1.6%
EV / EBIT historical average (5Y)
61.9×
reciprocal yield 1.6%
EV / EBITDA historical average (3Y)
31.2×
reciprocal yield 3.2%
EV / EBITDA historical average (5Y)
31.2×
reciprocal yield 3.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-02

Profitability

9 metrics
Gross margin
76.0%
Operating margin
3.1%
Trailing 12 months
Net margin
-0.5%
Gross profit (TTM)
$2.78B
Operating profit (TTM)
$113.87M
Net income (TTM)
−$19.11M
Trailing 12 months
Diluted EPS (TTM)
$-0.08
FCF margin
15.3%
Effective tax rate
143.8%

Per share

11 metrics
Revenue per diluted share (TTM)
$18.55
Gross profit per diluted share (TTM)
$14.10
Operating profit per diluted share (TTM)
$0.58
EBITDA per diluted share (TTM)
$1.94
Net income per diluted share (TTM)
$-0.10
Operating cash flow per diluted share (TTM)
$3.44
Free cash flow per diluted share (TTM)
$2.84
Capital expenditures per diluted share (TTM)
$0.60
R&D per diluted share (TTM)
$4.93
Stock compensation per diluted share (TTM)
$1.12
Book value per share
$31.65

Growth

11 metrics
Revenue growth YoY
+32.0%
Year over year
Net income growth YoY
-18.3%
Revenue (TTM)
$3.66B
Trailing 12 months
EPS growth YoY
-18.6%
Shares change YoY
+0.8%
Year over year · more shares
Revenue CAGR (3Y)
+15.4%
Revenue CAGR (5Y)
+11.6%
EPS CAGR (3Y)
+33.9%
EPS CAGR (5Y)
-16.7%
FCF CAGR (3Y)
+136.3%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-0.3%
Return on assets
-0.2%
Debt / equity
0.7
Current ratio
2.4
EBITDA (TTM)
$378.82M
Free cash flow (TTM)
$557.86M
Quick ratio
1.3
Interest coverage
0.9
Net debt / EBITDA
9.1
Return on invested capital
—
Trailing 12 months
Net cash
−$3.44B
Latest balance sheet
Cash & equivalents
$736.01M
Total assets
$11.57B
Total debt
$4.17B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$676.62M
Capital expenditures (TTM)
$118.75M
R&D (TTM)
$979.65M
SG&A (TTM)
$1.43B
Stock compensation (TTM)
$219.60M
R&D / revenue
26.8%
Stock compensation / revenue
6.0%

Ownership (13F)

9 metrics
13F filers
568
13F filer change QoQ
+5
Institutional ownership
101.4%
Conviction holders (share of 13F filers)
2.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.1%
Holder tenure
17.1
Price vs estimated holder cost
-7.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.5%

Short interest

3 metrics
Short interest
7.3%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.16M
Insider-sentiment score
38 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1048477 CUSIP 09061G101 13F (30d) 453 filings 397 filers Visit website Investor relations